Magazine Article | July 5, 2018

Sage Therapeutics — Sitting On The Brink Of CNS Breakthroughs

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

Jeff Jonas, M.D., likes to talk about “challenging conventional wisdom.” He’s also fond of similar phrases such as “changing paradigms” and “thinking differently,” all of which he utters within the first 10 minutes of our interview. He is, after all, the CEO of Sage Therapeutics, a biopharma company well-known for being unconventional in its approach to developing drugs for CNS disorders.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: